QNRX QUOIN PHARMACEUTICALS LTD Product Launches 8-K Filing 2025 - Clinical Data Update Quoin Pharmaceuticals announced new clinical data showing that the benefits of their treatment QRX003 for Netherton Syndrome were reversed four weeks after stopping the treatment, indicating the treatment's effects are not lasting.Get access to all SEC 8-K filings of the QUOIN PHARMACEUTICALS LTD